VYNE Therapeutics Inc.

NASDAQ: VYNE · Real-Time Price · USD
0.40
-1.04 (-72.22%)
At close: Jul 30, 2025, 3:59 PM

VYNE Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
202K 84K 121K 198K 98K 76K 114K 135K 99K 6K 167K 126K 178K 2.29M 4.09M 4.26M 4.12M
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 12K n/a 903K 1.05M 795K 601K
Gross Profit
202K 84K 121K 198K 98K 76K 114K 135K 99K 6K 167K 114K 178K 1.39M 3.04M 3.46M 3.52M
Operating Income
-9.2M -12.77M -13.09M -10.4M -7.38M -6.83M -6.23M -10.32M -5.88M -7.98M -9.33M -8.29M -8.69M -12.04M 17.78M -18.78M -19.43M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-8.6M -12.01M -12.16M -9.39M -6.24M -6.15M -6.07M -10.04M -5.61M -7.75M -9.26M -8.23M -8.69M -12.02M -21.29M -19.92M -20.55M
Net Income
-8.61M -12.02M -12.16M -9.41M -6.25M -6.19M -6.58M -10.06M -5.62M -7.76M -9.46M -8.48M 4.67M -11.57M -21.29M -19.92M -20.55M
Selling & General & Admin
3.27M 3.17M 2.96M 3.29M 3.77M 3.88M 3.03M 3.22M 3.24M 3.71M 3.95M 4.3M 4.42M 8.2M 13.83M 15.84M 16.62M
Research & Development
6.12M 9.68M 10.25M 7.31M 3.71M 3.02M 3.32M 7.23M 2.73M 4.28M 5.55M 4.11M 4.45M 5.24M 6.98M 6.41M 6.33M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 78K 52K -3K 26K -35K -69K -57K
Operating Expenses
9.4M 12.85M 13.21M 10.59M 7.48M 6.91M 6.35M 10.45M 5.97M 7.99M 9.5M 8.41M 8.87M 13.43M 20.81M 22.24M 22.95M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a 2.34M n/a n/a 3K n/a 3.47M 1.07M 1.06M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a -9.49M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
9.4M 12.85M 13.21M 10.59M 7.48M 6.91M 6.35M 10.45M 5.97M 7.99M 9.5M 8.41M 8.87M 14.34M 21.86M 23.04M 23.55M
Income Tax Expense
n/a 4K n/a n/a n/a 37K n/a 20K 10K 13K n/a n/a n/a -448K 3.44M 1M 1M
Shares Outstanding (Basic)
42.67M 42.59M 42.59M 42.59M 42.58M 31.05M 3.28M 3.27M 3.26M 2.98M 3.22M 3.22M 3.08M 2.97M 2.89M 2.86M 2.71M
Shares Outstanding (Diluted)
42.67M 42.59M 42.59M 42.59M 42.58M 31.05M 3.28M 3.27M 3.26M 2.98M 3.22M 3.22M 3.08M 2.97M 2.89M 2.86M 2.71M
EPS (Basic)
-0.2 -0.28 -0.29 -0.22 -0.15 -0.2 -2.01 -3.08 -1.72 -2.6 -2.94 -2.63 1.52 -3.89 -7.36 -6.98 -7.57
EPS (Diluted)
-0.2 -0.28 -0.29 -0.22 -0.15 -0.2 -2.01 -3.08 -1.72 -2.6 -2.94 -2.63 1.52 -3.89 -7.36 -6.98 -7.57
EBITDA
-9.19M -12.77M -13.09M -9.39M -7.38M -6.83M -6.23M -10.04M -5.88M -7.75M -9.16M -8.28M -8.65M -11.99M -10.77M -18.82M -19.46M
EBIT
-9.2M -12.77M -13.09M -10.4M -7.38M -6.83M -6.23M -10.04M -5.88M -7.75M -9.33M -8.29M -8.69M -12.02M -10.8M -9.61M -9.81M
Depreciation & Amortization
6K n/a n/a 1M -777K -255K -39.59K 122.08K 41.58K -155K 171K 12K 44K 26K 28K 28K 27K